| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4447666
Max Phase: Preclinical
Molecular Formula: C24H28FN3O4
Molecular Weight: 441.50
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: C#CCN(Cc1ccc(F)cc1)c1ccc(NC(=O)OCC)c(NC(=O)OCC(C)C)c1
Standard InChI: InChI=1S/C24H28FN3O4/c1-5-13-28(15-18-7-9-19(25)10-8-18)20-11-12-21(26-23(29)31-6-2)22(14-20)27-24(30)32-16-17(3)4/h1,7-12,14,17H,6,13,15-16H2,2-4H3,(H,26,29)(H,27,30)
Standard InChI Key: JQNUIKXUJCAWNQ-UHFFFAOYSA-N
Associated Targets(Human)
Voltage-gated potassium channel subunit Kv7.4 100 Activities
Voltage-gated potassium channel subunit Kv7.5 49 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Voltage-gated potassium channel subunit Kv7.2 268 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 441.50 | Molecular Weight (Monoisotopic): 441.2064 | AlogP: 5.24 | #Rotatable Bonds: 9 |
| Polar Surface Area: 79.90 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
| #RO5 Violations: 1 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 12.28 | CX Basic pKa: | CX LogP: 5.49 | CX LogD: 5.49 |
| Aromatic Rings: 2 | Heavy Atoms: 32 | QED Weighted: 0.52 | Np Likeness Score: -1.36 |
References
| 1. Wang L, Qiao GH, Hu HN, Gao ZB, Nan FJ.. (2019) Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity., 10 (1): [PMID:30655942] [10.1021/acsmedchemlett.8b00315] |
Source
Source(1):